Supernus Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Supernus Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Supernus Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Supernus Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Supernus Pharmaceuticals Inc (Supernus) is a biopharmaceutical company focused on developing and commercializing products for neurological and psychiatric conditions. Its products provide treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD), hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company offers its products to pharmaceutical wholesalers, specialty pharmacies, distributors, pharmacies, hospitals, and other customers, including federal and state entities. The company's brand names include Qelbree, Gocovri, Oxtellar XR, Apokyn, Trokendi XR, Xadago, Myobloc, and Onapgo. Supernus collaborates with channel partners to license its products outside the US. Supernus is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9715 Key West Avenue, Rockville, Maryland, 20850
Website
www.supernus.com
Telephone
1 301 8382500
No of Employees
778
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SUPN (NASD)
Revenue (2024)
$719.0M
8.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-152.2%
(2024 vs 2023)
Market Cap*
$2.8B
Net Profit Margin (2024)
XYZ
-148.0%
(2024 vs 2023)
* As of and is in US$
Supernus Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| QELBREE: Attention-Deficit/Hyperactivity Disorder | Qelbree |
| ONAPGO: Dyskinesia | GOCOVRI |
| APOKYN: Hypomobility | ONAPGO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company partnered with MERGE to develop cutting-edge treatments for central nervous system diseases. |
| 2026 | Contracts/Agreements | In April, the company signed an asset purchase agreement to acquire NV-5138 (SPN-820) from Navitor Pharmaceuticals for US$350 million. |
| 2025 | Acquisitions/Mergers/Takeovers | In July, the company acquired Sage Therapeutics, Inc., a biotech company. |
Competitor Comparison
| Key Parameters | Supernus Pharmaceuticals Inc | Glenmark Pharmaceuticals Ltd | Vanda Pharmaceuticals Inc | Acorda Therapeutics Inc | Lipocine Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | India | United States of America | United States of America | United States of America |
| City | Rockville | Mumbai | Washington | Pearl River | Salt Lake |
| State/Province | Maryland | Maharashtra | WashingtonD.C. | New York | Utah |
| No. of Employees | 778 | 13,477 | 533 | 102 | 14 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Charles W. Newhall, III | Chairman | Executive Board | 2016 | 81 |
| Jack A. Khattar | Chief Executive Officer; President; Secretary; Director | Executive Board | 2005 | 63 |
| Timothy C. Dec | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 67 |
| Frank Mottola | Senior Vice President; Chief Technology Officer | Senior Management | 2025 | 54 |
| Jonathan Rubin, MD | Senior Vice President - Research and Development; Chief Medical Officer | Senior Management | 2021 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer